On BSE, 19,386 shares were traded in the counter. The scrip had an average daily volume of 53,490 shares in the past one quarter.

The stock hit a high of Rs 337 and a low of Rs 328 so far during the day. The stock had a 52-week high of Rs 383 on 19 December 2007 and a 52-week low of Rs 231.25 on 27 August 2007.

The mid-cap pharma scrip had outperformed the market over the past one month till 15 April 2008, gaining 11.53% compared to the Sensex’s return of 9.08%. It had outperformed the market in the past one quarter, declining 6.35% compared to Sensex’s decline of 18.70%.

The company’s current equity is Rs 41.80 crore. Face value per share is Rs 2.

The current price of Rs 333 discounts its Q3 December 2007 annualized EPS of Rs 14.13 by a PE multiple of 23.56.

As a part of the agreement, Khandelwal Laboratories (K-Lab) will provide Nicholas Piramal India (NPIL) with certain patents' use and non-compete assurances for Cefixime and Camylofin based drugs.

Anafortan is the only smooth muscle, anti-spasmodic drug of its kind in India having revenues of Rs 22.9 crore in the year ended March 2008.

CEFI Group consists of third-generation, wide-application, Cefixime-based formulations in pure and combination forms. CEFI Group had revenues of Rs 26.2 crore in the year ended March 2008.

On 23 January 2008, Nicholas Piramal acquired pharmaceuticals business of Healthline, Bangalore for a consideration of Rs 15 crore.

On 19 December 2007, the company entered into a joint venture with Arkray of Japan to market diagnostic products, mainly self-monitoring blood glucose systems in the Indian market.

Nicholas Piramal India’s net profit rose 70.5% to Rs 73.82 crore on 19.2% growth in net sales to Rs 486.21 crore in Q3 December 2007 over Q3 December 2006.

Nicholas Piramal India is one among the top ten pharmaceutical contract-manufacturing firms in the world.